Abstract
The clinical value of the reverse transcription polymerase chain reaction (RT-PCR) assay for tyrosinase in peripheral blood of melanoma patients is still under debate. A total of 212 blood samples from 212 melanoma patients in all clinical stages (AJCC) were examined. Erythrocytes were lysed prior to RNA extraction by phenol precipitation from 2.7 ml of blood. cDNA for tyrosinase PCR was synthesized using random hexamers. Positive tyrosinase RT-PCR results were obtained in 11% of 106 stage I patients, 18% of 56 stage II patients, 31% of 26 stage III patients and 67% of 24 stage IV patients. After a median follow-up of 36 months (range 26–41), stage III patients with positive RT-PCR for tyrosinase had a shortened disease-free interval as compared to negative patients (P< 0.01). In stage IV patients, median overall survival was 8 months in case of a positive RT-PCR in contrast to 12 months in case of a negative test. While univariate analysis showed sex and primary tumour location associated with positive RT-PCR, multiple regression analysis revealed clinical stage and detection of tyrosinase transcripts in peripheral blood as best prognostic factors. Hazard ratios for disease-free survival were 19.7 (confidence interval (CI) 8.53–45.5, P = 0.0001) for metastatic vs primary disease and 2.96 (Cl 1.49–5.89, P = 0.002) for positive vs negative tyrosinase RT-PCR. The corresponding hazard ratios for overall survival were 97.0 (Cl 12.7–741, P = 0.0001) and 4.33 (Cl 1.69–11.1, P = 0.002). Our results emphasize the importance of tyrosinase RT-PCR testing in peripheral blood. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Balch CM, Soong SW and Shaw HM (1985) An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide, Balch CM, Milton GW (eds), pp. 321–352. Lippincott: Philadelphia
Battyani Z, Grob JJ and Xerri L, et al (1995) Polymerase chain reaction of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 131: 443–447
Brossart P, Keilholz U and Willhauck M, et al (1993) Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 101: 887–889
Brossart P, Keilholz U and Scheibenbogen C, et al (1994) Detection of residual tumour cells in patients with malignant melanoma responding to immunotherapy. J Immunother 15: 38–41
Farthmann B, Eberle J, Krasagakis K, Gstöttner M, Wang N, Bisson S and Orfanos CE (1998) RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Dermatol 110: 263–267
Foss AJE, Guille MJ and Occleston NL, et al (1995) The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 72: 155–159
Ghossein RA, Coit D, Brennan M, Zhang ZF, Wang Y, Bhattacharya, Houghton A and Rosai J (1998) Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res 4: 419–428
Gläser R, Rass K and Seiter S, et al (1997) Detection of ciculating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 15: 2818–2825
Hoon DSB, Wang Y and Dale PS, et al (1995) Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13: 2109–2115
Jung FA, Buzaid AC and Merrick IR, et al (1997) Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 15: 2826–2831
Keilholz U, Willhauck M and Rimoldi D (1998) Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumor cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur J Cancer 34: 750–753
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Bordern EC and Blum RH (1996) Interferon-alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol 14: 7–17
Kunter U, Buer J and Probst M, et al (1996) Peripheral blood tyrosinase messenger RNA detection in malignant melanoma. J Natl Cancer Inst 889: 569–570
Kwon BS, Haq AK and Pomerantz SH, et al (1987) Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci USA 84: 7473–7477
Mellado B, Colomer D and Castel T, et al (1996) Detection of circulating neoplastic cells by reverse transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 14: 2091–2097
Pitman K, Burchill S and Smith B, et al (1996) Reverse transcriptase polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Annal Oncol 7: 197–201
Ponnazhagen S, Hou L and Kwon BS (1994) Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region. J Invest Dermatol 102: 744–748
Proebstle T, Huber R and Sterry W (1996) Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase mRNA. Eur J Cancer 32A: 1664–1667
Reinhold U, Lüdke-Handjery HC and Schnautz S, et al (1997) The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol 108: 166–169
Schwürzer-Voit M, Proebstle TM and Sterry W (1996) Identification of lymph node metastases by use of PCR in melanoma patients. Eur J Cancer 32A: 264–268
Smith B, Selby P and Southgate J, et al (1991) Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338: 1227–1229
Van der Velde, Zimmermann D, Roijers JF and Bouwens-Rombuds A, et al (1996) Molecular test for the detection of tumor cells in blood and sentinel nodes. Am J Pathol 149: 759–764
Wang X, Heller R and VanVoorhis N, et al (1994) Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 220: 768–774
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Proebstle, T., Jiang, W., Högel, J. et al. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br J Cancer 82, 118–123 (2000). https://doi.org/10.1054/bjoc.1998.0887
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1998.0887
Keywords
This article is cited by
-
Application of a Filtration- and Isolation-by-Size Technique for the Detection of Circulating Tumor Cells in Cutaneous Melanoma
Journal of Investigative Dermatology (2010)
-
Circulating tumor cells in solid cancer: Tumor marker of clinical relevance?
Current Oncology Reports (2008)
-
Risikoadaptierte Nachsorge von Melanompatienten
Der Onkologe (2007)
-
Circulating Tyrosinase and MART-1 mRNA does not Independently Predict Relapse or Survival in Patients with AJCC Stage I–II Melanoma
Journal of Investigative Dermatology (2006)
-
Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients
British Journal of Cancer (2003)